Skip to main content
. 2011 Dec;39(12):2182–2190. doi: 10.1124/dmd.111.040212

Fig. 1.

Fig. 1.

Steady-state plasma concentration versus time profiles for silybin B conjugates and parent silybin B (inset) at 280 mg of silymarin in HCV (●) and NAFLD (□) subjects. Forty-eight-hour plasma samples were obtained after a final single-dose administration after an every 8 h for 7-day dose regimen. AUC0–8 h and Cmax for silybin B conjugates were 46 and 42% lower, respectively, in NAFLD subjects compared with HCV; p < 0.05.